NanoZymeX
Developing a lipid nanoparticle platform for enhanced enzyme replacement therapy.
About
NanoZymeX is a biotech startup spun out of research at the University of Basel. The company is developing a novel platform utilizing lipid nanoparticles to improve enzyme replacement therapies for rare genetic conditions, such as Pompe disease. Their technology aims to enhance the delivery of therapeutic enzymes into target cells and lysosomes, thereby increasing therapeutic activity in affected tissues and reducing immune responses to repeated treatments. Teams look it up for Biotechnology, Rare Diseases, Drug Delivery.
Frequently asked
What does NanoZymeX do?
NanoZymeX is a Biotechnology company that offers Platform. Teams look it up for Rare Diseases, Drug Delivery, Therapeutics. It is based in Basel, Switzerland. Public records show $160K in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has NanoZymeX raised?
NanoZymeX has raised a total of $160K in funding. The most recent round on record is Pre-Seed.
Where is NanoZymeX headquartered?
NanoZymeX is headquartered in Basel, Switzerland.
What industry does NanoZymeX operate in?
NanoZymeX operates in Biotechnology, Rare Diseases, Drug Delivery, Therapeutics.